Extension of 2004 agreement focuses on central nervous system diseases.



Euroscreen extended the term of an agreement with Cephalon to collaborate on multiple drug discovery programs through 2009.


Euroscreen and Cephalon initiated the collaboration in 2004 to discover and develop small molecule therapeutics focused upon central nervous system diseases and targeting GPCRs. The companies apply the AequoScreen™ proprietary functional assay technology in their efforts to generate novel small molecule leads across a broad range of GPCR targets.


Under the terms of the agreement, Euroscreen will receive R&D payments and additional milestone payments for successful programs. Euroscreen retains rights to programs that are not pursued by Cephalon.








This site uses Akismet to reduce spam. Learn how your comment data is processed.